PREFER - Why, when and how to assess and use patient preferences in medical product decision-making
Published February 24, 2022 | Version v1
Other Open

Treating non-small cell lung cancer: What do patients PREFER

Creators

  • 1. Alexion
  • 2. European Institute of Oncology

Contributors

  • 1. KU Leuven
  • 2. University Medical Centre Utrecht
  • 3. European Cancer Patient Coalition
  • 4. Erasmus University Rotterdam
  • 5. European Institute of Oncology

Description

We wanted to learn about lung cancer patients’ preferences for new treaments, and what they considered to be the maximum acceptable risk, and the minimum acceptable benefit of a treatment.

Files

Treating non-small cell lung cancer - What do patients PREFER.pdf

Files (795.4 kB)

Additional details

Funding

European Commission
PREFER – Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 115966